Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Get Free Report)'s share price gapped up prior to trading on Wednesday . The stock had previously closed at $31.64, but opened at $34.86. Ascentage Pharma Group International shares last traded at $35.00, with a volume of 7,496 shares.
Analyst Upgrades and Downgrades
Separately, JPMorgan Chase & Co. started coverage on shares of Ascentage Pharma Group International in a research report on Thursday, March 27th. They set an "overweight" rating for the company.
Check Out Our Latest Research Report on Ascentage Pharma Group International
Ascentage Pharma Group International Stock Up 13.4%
The stock's 50 day moving average is $25.12. The company has a debt-to-equity ratio of 3.24, a current ratio of 1.26 and a quick ratio of 1.26.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Ascentage Pharma Group International stock. Monashee Investment Management LLC purchased a new stake in shares of Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 159,942 shares of the company's stock, valued at approximately $3,511,000. Monashee Investment Management LLC owned 0.18% of Ascentage Pharma Group International as of its most recent filing with the Securities and Exchange Commission (SEC).
Ascentage Pharma Group International Company Profile
(
Get Free Report)
Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.
Featured Stories
Before you consider Ascentage Pharma Group International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascentage Pharma Group International wasn't on the list.
While Ascentage Pharma Group International currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
